Difference between revisions of "Non-small cell lung cancer, RET-positive"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Tag: visualeditor
m
Line 10: Line 10:
 
Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens.
 
Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens.
  
−
== Metastatic disease ==
 
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
{| class="wikitable" style="float:right; margin-right: 5px;"
 
|-
 
|-
 
|<div align="right" style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>1 [[Tutorial#Regimens|regimens]] on this page</b></font></div><div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|<div align="right" style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>1 [[Tutorial#Regimens|regimens]] on this page</b></font></div><div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
 
|}
 
|}
−
===Selpercatinib monotherpay===
+
=Advanced or metastatic disease=
−
'''Regimen'''
+
==Selpercatinib monotherapy {{#subobject:ea894c|Regimen=1}}==
−
{| class="wikitable"
+
{| class="wikitable" style="float:right; margin-left: 5px;"
−
!FDA-recommended dose
+
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:9134b2|Variant=1}}===
 +
{| class="wikitable" style="color:white; background-color:#404040"
 +
|<small>'''FDA-recommended dose'''</small>
 +
|-
 
|}
 
|}
−
{| class="wikitable"
+
{| class="wikitable" style="width: 50%; text-align:center;"  
−
!Study
+
!style="width: 50%"|Study
−
!Years of enrollment
+
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
−
!Evidence
+
|-
 +
|[https://www.jto.org/article/S1556-0864(19)30742-7/fulltext Drilon et al. 2019 (LIBRETTO-001)]
 +
| style="background-color:#91cf61" |Phase I/II (RT)
 
|-
 
|-
−
|Drilon et al. 2019
 
−
 
−
LIBRETTO-001
 
−
|
 
−
|Phase I/II
 
 
|}
 
|}
−
'''Biomarker eligibility criteria'''
+
====Biomarker eligibility criteria====
−
 
+
*RET fusion positive
−
*Biomarker: RET fusion positive
 
−
 
 
−
'''Chemotherapy'''
 
  
−
*Selpercatinib 120 mg (<50 kg) and 160 mg (<u>></u>50 kg) orally twice daily with or without food
+
====Chemotherapy====
 +
*[[Selpercatinib (Retevmo)]] with or without food, as follows:
 +
**Less than 50 kg: 120 mg PO twice per day
 +
**50 kg or more: 160 mg PO twice per day
  
 
'''Continued indefinitely'''
 
'''Continued indefinitely'''
  
−
'''References'''
+
===References===
  
−
#'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract.]
+
#'''Abstract.''' Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. [https://www.jto.org/article/S1556-0864(19)30742-7/fulltext link to abstract]
  
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Lung cancers]]
 
[[Category:Lung cancers]]

Revision as of 01:45, 30 July 2020

Page editor Section editor
Amit Kulkarni.jpg
 Amit Kulkarni, MBBSUniversity of MinnesotaMinneapolis, MNSocial-twitter-icon.pngAmitKulkarniMD
TravisOsterman.jpg
 Travis Osterman, DO, MSVanderbilt UniversityNashville, TNSocial-twitter-icon.pngTravisOstermanLinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.

1 regimens on this page
7 variants on this page

Advanced or metastatic disease

Selpercatinib monotherapy

back to top

Regimen

FDA-recommended dose
Study Evidence
Drilon et al. 2019 (LIBRETTO-001) Phase I/II (RT)

Biomarker eligibility criteria

  • RET fusion positive

Chemotherapy

  • Selpercatinib (Retevmo) with or without food, as follows:
    • Less than 50 kg: 120 mg PO twice per day
    • 50 kg or more: 160 mg PO twice per day

Continued indefinitely

References

  1. Abstract. Drilon, A., Oxnard, G., Wirth, L., Besse, B., Gautschi, O., Tan, S.W.D., Loong, H., Bauer, T., Kim, Y.J., Horiike, A., Park, K., Shah, M., McCoach, C., Bazhenova, L., Seto, T., Brose, M., Pennell, N., Weiss, J., Matos, I., Peled, N., Cho, B.C., Ohe, Y., Reckamp, K., Boni, V., Satouchi, M., Falchook, G., Akerley, W., Daga, H., Sakamoto, T., Patel, J., Lakhani, N., Barlesi, F., Burkard, M., Zhu, V., Moreno Garcia, V., Medioni, J., Matrana, M., Rolfo, C., Lee, D.H., Nechushtan, H., Johnson, M., Velcheti, V., Nishio, M., Toyozawa, R., Ohashi, K., Song, L., Han, J., Spira, A., De Braud, F., Staal Rohrberg, K., Takeuchi, S., Sakakibara, J., Waqar, S., Kenmotsu, H., Wilson, F., B.Nair, Olek, E., Kherani, J., Ebata, K., Zhu, E., Nguyen, M., Yang, L., Huang, X., Cruickshank, S., Rothenberg, S., Solomon, B., Goto, K., Subbiah, V. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. link to abstract
Retrieved from "https://hemonc.org/w/index.php?title=Non-small_cell_lung_cancer,_RET-positive&oldid=45161"